208 related articles for article (PubMed ID: 36625031)
1. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present).
Shi X; Zhao T; da Silva-Júnior EF; Zhang J; Xu S; Gao S; Liu X; Zhan P
Expert Opin Ther Pat; 2022 Dec; 32(12):1175-1184. PubMed ID: 36625031
[TBL] [Abstract][Full Text] [Related]
2. Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019).
Dong Y; Zhao T; Ai W; Zalloum WA; Kang D; Wu T; Liu X; Zhan P
Expert Opin Ther Pat; 2019 Nov; 29(11):871-879. PubMed ID: 31593642
[No Abstract] [Full Text] [Related]
3. Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout.
Hou Z; Ma A; Mao J; Song D; Zhao X
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):895-909. PubMed ID: 37994776
[TBL] [Abstract][Full Text] [Related]
4. Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models.
Li X; Yan Z; Tian J; Zhang X; Han H; Ye F
Ann Clin Lab Sci; 2019 Nov; 49(6):756-762. PubMed ID: 31882426
[TBL] [Abstract][Full Text] [Related]
5. A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications.
Song D; Zhao X; Wang F; Wang G
Eur J Pharmacol; 2021 Sep; 907():174291. PubMed ID: 34216576
[TBL] [Abstract][Full Text] [Related]
6. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
Tan PK; Liu S; Gunic E; Miner JN
Sci Rep; 2017 Apr; 7(1):665. PubMed ID: 28386072
[TBL] [Abstract][Full Text] [Related]
7. DKB114, A Mixture of
Lee YS; Kim SH; Yuk HJ; Kim DS
Nutrients; 2018 Sep; 10(10):. PubMed ID: 30274153
[No Abstract] [Full Text] [Related]
8. Discovery of Novel Biphenyl Carboxylic Acid Derivatives as Potent URAT1 Inhibitors.
Hou X; Wang Y; Yang Y; Xiao Z
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959834
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Flexible Naphthyltriazolylmethane-based Thioacetic Acids as Highly Active Uric Acid Transporter 1 (URAT1) Inhibitors for the Treatment of Hyperuricemia of Gout.
Zhang X; Wu J; Liu W; Liu Y; Xie Y; Shang Q; Zhou Z; Xu W; Tang L; Wang J; Zhao G
Med Chem; 2017; 13(3):260-281. PubMed ID: 27633583
[TBL] [Abstract][Full Text] [Related]
10. (E)-2-(4-bromophenyl)-1-(2, 4-dihydroxyphenyl)ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1.
Hu Q; Zhou M; Zhu H; Lu G; Zheng D; Li H; Hao K
Biomed Pharmacother; 2017 Feb; 86():88-94. PubMed ID: 27951420
[TBL] [Abstract][Full Text] [Related]
11. Discovery of digallic acid as XOD/URAT1 dual target inhibitor for the treatment of hyperuricemia.
Zheng F; Mai S; Cen X; Zhao P; Ye W; Ke J; Lin S; Hu H; Guo Z; Zhang S; Liao H; Wu T; Tian Y; Zhang Q; Pang J; Zhao Z
Bioorg Chem; 2024 Jun; 147():107381. PubMed ID: 38669781
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel curcumin derivatives targeting xanthine oxidase and urate transporter 1 as anti-hyperuricemic agents.
Ao GZ; Zhou MZ; Li YY; Li SN; Wang HN; Wan QW; Li HQ; Hu QH
Bioorg Med Chem; 2017 Jan; 25(1):166-174. PubMed ID: 28340987
[TBL] [Abstract][Full Text] [Related]
13. Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase.
Chen Y; Zhao Z; Li Y; Yang Y; Li L; Jiang Y; Lin C; Cao Y; Zhou P; Tian Y; Wu T; Pang J
Phytomedicine; 2021 Jan; 80():153374. PubMed ID: 33075645
[TBL] [Abstract][Full Text] [Related]
14. Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout.
Tan PK; Farrar JE; Gaucher EA; Miner JN
Mol Biol Evol; 2016 Sep; 33(9):2193-200. PubMed ID: 27352852
[TBL] [Abstract][Full Text] [Related]
15. Omega-3 Polyunsaturated Fatty Acids Inhibit the Function of Human URAT1, a Renal Urate Re-Absorber.
Saito H; Toyoda Y; Takada T; Hirata H; Ota-Kontani A; Miyata H; Kobayashi N; Tsuchiya Y; Suzuki H
Nutrients; 2020 May; 12(6):. PubMed ID: 32486008
[TBL] [Abstract][Full Text] [Related]
16. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors.
Zhang J; Dong Y; Gao S; Zhang X; Liao H; Shi X; Zhang Z; Zhao T; Liang R; Qi D; Wu T; Pang J; Liu X; Zhan P
Eur J Med Chem; 2022 Dec; 244():114816. PubMed ID: 36219903
[TBL] [Abstract][Full Text] [Related]
18. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
[TBL] [Abstract][Full Text] [Related]
19. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Torres RJ; Puig JG
Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
[TBL] [Abstract][Full Text] [Related]
20. Recent approaches to gout drug discovery: an update.
Otani N; Ouchi M; Kudo H; Tsuruoka S; Hisatome I; Anzai N
Expert Opin Drug Discov; 2020 Aug; 15(8):943-954. PubMed ID: 32329387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
